4beta-hydroxycholesterol in Cirrhosis
Reason given: COVID pandemia and organisational changes hinder recruitment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- University of Oulu
- Trial code
- NCT04199910
- Record updated
- 5 May 2026
- Original description
The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.Read full original descriptionShow less
4beta-hydroksikolesteroli Maksakirroosissa
The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.
Inclusion: Patients with cirrhosis, pneumonia, Crohn's disease or colitis ulcerosa; Treated in the ward 42 of the Oulu University Hospital.
Exclusion: None.